Company Overview of GlaxoSmithKline LLC
GlaxoSmithKline LLC focuses on discovering, developing, and delivering medicines, vaccines, and other healthcare products for customers in the United States. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. The company also provides vaccines for children and adults; and over-the-counter products. GlaxoSmithKline LLC was formerly known as SmithKline Beecham Corporation. The company was incorporated in 1929 and is based in Philadelphia, Pennsylvania. GlaxoSmithKline LLC operates as a subsidiary of GlaxoSmith...
5 Crescent Drive
Philadelphia, PA 19112
Founded in 1929
Key Executives for GlaxoSmithKline LLC
Compensation as of Fiscal Year 2015.
GlaxoSmithKline LLC Key Developments
GlaxoSmithKline LLC Wins $13 Million Federal Contract
Dec 30 14
GlaxoSmithKline LLC won a $13,000,127 federal contract from the U.S. Department of Health and Human Services' Office of the Secretary for the advanced research and development of chemical, biological, radiological and nuclear medical countermeasures for the Biomedical Advanced Research and Development Authority.
GlaxoSmithKline LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 09:00 AM
Sep 10 14
GlaxoSmithKline LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 09:00 AM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Katy Moore, Senior Director, Scientific Licensing, Worldwide Business Development.
North Carolina Court Denies Motion to Dismiss, Brought by GlaxoSmithKline LLC
Aug 26 14
Genetic Technologies Limited announced that the United States District Court for the Middle District of North Carolina issued an Order denying a motion brought by GlaxoSmithKline LLC (GSK) to dismiss the patent infringement lawsuit brought against it by GTG. This action was initially brought by GTG against GSK in 2011, in the District Court of Colorado, but was then moved at the request of GSK to the District Court for the Middle District of North Carolina. Thereafter, both sides filed motions in support of their different legal perspectives. Most recently on June 27, 2014, GSK moved to have GTG’s Second Amended Complaint dismissed, arguing the relevant GTG patent covers natural phenomena or laws of nature that are not entitled to patent protection, and that the Court should therefore dismiss the action. On August 22, 2014, the Court issued an Order denying GSK’s motion to dismiss.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|